← Leaderboards
Gerburg M Wulf
Beth Israel Deaconess Medical Center
$4,301,499
Attributed
$5,374,238
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,374,238 · 6
By mechanism
R01$3,416,285 · 2
R21$1,006,367 · 2
K08$651,646 · 1
R56$299,940 · 1
Top collaborators
- Yu Jing Jan Heng4 shared
- Nathanael Schiander Gray2 shared
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Lewis C Cantley$35,988,650
- Yu Jing Jan Heng$417,870
- Mark A Herman$6,685,137
- Rajiv R Ratan$2,742,688
- Kun Ping Lu$22,478,971
Others in their field
Top investigators on “Cancer Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$366,127,178
- Norman Wolmark · Nsabp Foundation, Inc.$292,963,206
- Gregory H Reaman · National Childhood Cancer Foundation$271,061,526
- Peter C Adamson · National Childhood Cancer Foundation$269,808,480
- Charles A Coltman · Southwest Oncology Group$178,303,465
- Sudhir Raju · Ctis, Inc.$162,436,462
Research focus
Cancer TherapyMouse ModelMalignant Breast NeoplasmTumorNeoplastic CellIn VivoEstrogen Receptor PositiveMutationSignal TransductionPharmaceutical PreparationsResistanceTreatment OutcomeMutantMammary NeoplasmsTreatment StrategyTriple-Negative Invasive Breast CarcinomaEnzymesBreast Cancer CellMalignant NeoplasmsCell LineEstrogen ReceptorsLeadCellsResponse
Grant awards (19)
Determinants of PARP-inhibitor response in Breast Cancer Patients without germline mutations in BRCA1/2$470,567
R21 · FY2025 · CA · contact PI
Gender-Affirming Testosterone Therapy on Breast Cancer Risk and Treatment Outcomes$299,940
R56 · FY2023 · CA
Gender-affirming estrogen therapy and breast cancer treatment outcome$200,442
R21 · FY2023 · CA
Admin Suppl Gender-affirming estrogen therapy and breast cancer treatment outcome$89,920
R21 · FY2023 · CA
Novel Uses of PI3K-inhibitors for the Treatment of advanced PIK3CA-mutant Breast Cancer$392,306
R01 · FY2022 · CA · contact PI
Gender-affirming estrogen therapy and breast cancer treatment outcome$245,438
R21 · FY2022 · CA
Development of selective Pin1 inhibitors to target a common oncogenic mechanism$654,869
R01 · FY2021 · CA · contact PI
Novel Uses of PI3K-inhibitors for the Treatment of advanced PIK3CA-mutant Breast Cancer$400,313
R01 · FY2021 · CA · contact PI
Optimization of PI3K-inhibitors to augment the efficacy of microtubule-disrupting chemotherapy$124,999
R01 · FY2021 · CA · contact PI
Development of selective Pin1 inhibitors to target a common oncogenic mechanism$654,869
R01 · FY2020 · CA · contact PI
Novel Uses of PI3K-inhibitors for the Treatment of advanced PIK3CA-mutant Breast Cancer$400,313
R01 · FY2020 · CA · contact PI
Novel Uses of PI3K-inhibitors for the Treatment of advanced PIK3CA-mutant Breast Cancer$388,303
R01 · FY2019 · CA · contact PI
Novel Uses of PI3K-inhibitors for the Treatment of advanced PIK3CA-mutant Breast Cancer$400,313
R01 · FY2018 · CA · contact PI
Role of the Prolylisomerase Pin1 in Oncogenesis$65,165
K08 · FY2007 · CA · contact PI
Role of the Prolylisomerase Pin1 in Oncogenesis$130,329
K08 · FY2006 · CA · contact PI
Role of the Prolylisomerase Pin1 in Oncogenesis$130,329
K08 · FY2005 · CA
Role of the Prolylisomerase Pin1 in Oncogenesis$130,329
K08 · FY2004 · CA
Role of the Prolylisomerase Pin1 in Oncogenesis$130,329
K08 · FY2003 · CA
Role of the Prolylisomerase Pin1 in Oncogenesis$65,165
K08 · FY2002 · CA